Business of Biotech Podcast: BoB @ JPM: Marc Salzberg, M.D., Airway Therapeutics
January 19, 2026
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 – 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian talks about why he selected BPD as a lead clinical indication (a disease primarily affecting preterm infants), what he learned through founding and selling a CRO, how a private biotech funds a pivotal trial across continents, and offers an industry outlook for 2026.